THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [7.2] ID: TIP-MED-000104

Diclofenac (Diclofenac Sodium & Diclofenac Potassium)

Active Ingredient / Scientific Identity: Diclofenac • Class: Non-Steroidal Anti-Inflammatory Drug (NSAID); Non-Selective COX-1 and COX-2 Inhibitor (Relatively Higher COX-2 Selectivity)

⚖️ Compare Profile
Generic / Entity NameDiclofenac (Diclofenac Sodium & Diclofenac Potassium) ([7.2])
Verified Indian Brands / RefBrufen (Abbott), Ibugesic (Cipla)
Pharmacological ClassNon-Steroidal Anti-Inflammatory Drug (NSAID); Non-Selective COX-1 and COX-2 Inhibitor (Rel
Available Dosage FormsEnteric-Coated (Diclofenac Sodium) & Immediate-Release (Diclofenac Potassium) Tablets: 50 mg; Sustained-Releas
Regulatory ClassificationSchedule H Prescription Drug • Veterinary Use Banned in India (Drugs Rules Rule 105B)
Key Warning & Review DateMonitor transaminases; contraindicated in severe hepatic impairment.
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H Prescription Drug • Veterinary Use Banned✔️ Standard Clinical Dispensing Precautions

1. Clinical & Scientific Overview

Diclofenac (Diclofenac Sodium & Diclofenac Potassium) (TIP-MED-000104, Reference Code [7.2]) is classified under Pain, Inflammation, Rheumatology & Gout Medicines (Ch 07) as a Non-Steroidal Anti-Inflammatory Drug (NSAID); Non-Selective COX-1 and COX-2 Inhibitor (Relatively Higher COX-2 Selectivity). Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug • Veterinary Use Banned in India (Drugs Rules Rule 105B).

Verified Indian Market Examples / Compendial Status:
Brufen (Abbott), Ibugesic (Cipla)
Representative Indian Market Examples (Edition 2.7 Ch 07 [7.2], p. 79): Voveran / Voveran-SR (Novartis/Dr. Reddy's), Reactin (Cipla), Dynapar / Dynapar-AQ (Troikaa), Jonac; Topical Gel: OmniGel, Volini, Voveran Emulgel; In FDC with Paracetamol: Voveran-Plus — Strengths & Forms: Enteric-Coated (Diclofenac Sodium) & Immediate-Release (Diclofenac Potassium) Tablets: 50 mg; Sustained-Release (SR) Tablets: 75 mg, 100 mg; IM/IV Injection: 75 mg/3 mL or 75 mg/1 mL (AQ); Suppository: 50 mg, 100 mg; Topical Gel: 1% w/w
Dosage Forms & Available Strengths:
Enteric-Coated (Diclofenac Sodium) & Immediate-Release (Diclofenac Potassium) Tablets: 50 mg; Sustained-Release (SR) Tablets: 75 mg, 100 mg; IM/IV Injection: 75 mg/3 mL or 75 mg/1 mL (AQ); Suppository: 50 mg, 100 mg; Topical Gel: 1% w/w
Routes: Oral / Parenteral / Topical as specified by formulation

3. Mechanism of Action & Pharmacodynamics

Reversibly inhibits cyclooxygenase isoenzymes COX-1 and COX-2 (with ~4- to 10-fold relative preference for COX-2), blocking conversion of arachidonic acid to pro-inflammatory prostaglandins (PGE2, PGI2) in peripheral tissues and synovial fluid. Accumulates in synovial fluid for 12+ hours despite a short 1–2 hour plasma half-life.

4. Therapeutic Indications & Evidence-Supported Uses

  • Acute musculoskeletal pain, postoperative pain, dysmenorrhoea, and acute gouty arthritis
  • Rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis
  • Acute renal colic (ureteric spasm relief via PGE2 inhibition)

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: Adults: 50 mg orally 2–3 times daily (or 75–100 mg SR once daily; max 150 mg/day) for the shortest duration necessary. Topical Gel (1% w/w): apply 2–4 g 3–4 times daily.

Administration & Meal Timing: Oral (take after meals), Topical, or Deep Intramuscular / IV infusion.

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Metabolism & Biotransformation:
Monitor transaminases; contraindicated in severe hepatic impairment.
Elimination & Renal Adjustment:
Contraindicated in eGFR < 30 mL/min; inhibits vasodilatory renal prostaglandins (PGE2/PGI2) and constricts the afferent arteriole, precipitating acute kidney injury.
Hepatic Impairment Considerations:
Monitor transaminases; contraindicated in severe hepatic impairment.

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • Active peptic ulceration or gastrointestinal bleeding
  • Established ischaemic heart disease, peripheral arterial disease, cerebrovascular disease, or congestive heart failure (NYHA II–IV) — high COX-2 prothrombotic CV risk
  • NSAID/Aspirin-exacerbated respiratory disease (AERD / Samter's triad)
  • Third trimester of pregnancy (premature closure of foetal ductus arteriosus) and CKD (eGFR < 30 mL/min)

Key Clinical Precautions: Monitor transaminases; contraindicated in severe hepatic impairment.

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Gastrointestinal erosion, peptic ulceration, and GI haemorrhage
  • Cardiovascular thrombotic events (myocardial infarction, stroke) — Diclofenac carries a CV risk comparable to selective coxibs due to high COX-2 inhibition
  • Afferent arteriolar vasoconstriction, sodium/water retention, hyperkalaemia, and papillary necrosis
Serious / Dose-Limiting Adverse Effects:
  • Hepatocellular transaminase elevation

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

  • ACE Inhibitors / ARBs (Telmisartan) + Diuretics (Furosemide): 'Triple Whammy' acute kidney injury (afferent constriction + efferent dilation + hypovolaemia)
  • Antiplatelets (Aspirin, Clopidogrel), Anticoagulants (Warfarin, Apixaban), SSRIs, Corticosteroids: marked increase in upper GI ulceration and bleeding
  • Lithium & Methotrexate: decreases renal clearance and precipitates severe toxicity

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.

Pharmacist Patient Counselling Points:

  • Take immediately after food with a full glass of water, and use the lowest effective dose for the shortest possible number of days.
  • Consider co-prescribing a Proton Pump Inhibitor (Pantoprazole) in patients aged >60 yr or on low-dose Aspirin.
  • LEGAL NOTE: Human Diclofenac multi-dose vials are banned for veterinary use in India (single-dose 1 mL human ampoules only) because Diclofenac caused catastrophic renal failure and near-extinction of Indian Gyps vultures.

Storage, Stability & Dispensing Safeguards: Store below 30°C.

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2026) • NLEM 2022 (MoHFW) • CDSCO Approved Prescribing Information

Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.